In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines

Oncology Research

Volumn 15, Issue 1, 2005, Pages 39-48

  Loprevite, Maura ^a   Tiseo, Marcello ^a   Grossi, Francesco ^a   Scolaro, Tindaro ^a   Semino, Claudia ^a   Pandolfi, Alessandra ^b   Favoni, Roberto ^a   Ardizzoni, Andrea ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b PFIZER INC   (United States)

^c Azienda Ospedaliera Universitaria   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Cell lines; CI 994; Combined therapy; Deacetylase inhibitors; Lung cancer; Preclinical investigation

Indexed keywords

4 N ACETYLDINALINE; DOCETAXEL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IRRADIATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL;

EID: 16344391638     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504005775082066     Document Type: Article

References (23)

1. Giaccone, G. Targeted therapy in non-small cell lung cancer. Lung Cancer 38(Suppl. 2):29-32; 2002.
2. Herbst, R. S. Targeted therapy in non-small-cell lung cancer. Oncology 16(9 Suppl. 9):19-24; 2002.
3. Bunn, P. A. Novel targeted agents for the treatment of lung cancer. Proc. ASCO 683; 2002.
4. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:1210-1216; 2000.
5. Kochbin, S.; Verdel, A.; Lemercier, C.; Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11:162-166; 2001.
6. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassini, L.; Gelmetti, V.; Cioce, M.; Fanelli, M.; Ruthardt, M.; Ferrara, F. F.; Zamir, I.; Seiser, C.; Grignani, F.; Lazar, M. A.; Minucci, S.; Pelicci, P. G. Fusion protein of the retinoic acid receptor-alpha recruits histone deacetylase in promyelocytic leukaemia. Nature 391:815-818; 1998.
7. Lin, R. J.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H., Jr.; Evans, R. M. Role of the histone deacetylase complex in the acute promyelocytic leukaemia. Nature 391:811-814; 1998.
8. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477-483; 2001.
9. Butler, L. M.; Webb, Y.; Agus, D. B.; Higgins, B.; Tolentino, T. R.; Kutko, M. C.; LaQuaglia, M. P.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H. I.; Breslow, R.; Richon, V. M.; Rifkind, R. A.; Marks, P. A. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 7:962-970; 2001.
10. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:5165-5170; 2000.
11. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7:759-760; 2001.
12. Kraker, A. J.; Mizzen, C. A.; Haiti, B. G.; Miin, J.; Allis, C. D.; Merriman, R. L. Modulation of histone acetylation by (4-(acetylamino)-N-(2- amino-phenyl)benzamide) in HCT-8 colon carcinoma. Mol. Cancer Ther. 2:401-408; 2003.
13. Carmichael, J.; De Graff, W. J.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemo-sensitivity testing. Cancer Res. 47:936-942; 1987.
14. Webb, J. L. Effect of more than one inhibitor. In: Enzymes and metabolic inhibitors, vol. 1. New York: Academic Press; 1963:66.
15. Kern, D. H.; Morgan, C. R.; Hildebrand-Zanki, S. U. In vitro pharmacodynamics of 1-beta-D-arabinofuranoylcytosine: Synergy of antitumor activity with diamminedichloroplatinum(II). Cancer Res. 48:117-121; 1988.
16. LoRusso, P. M.; Demchik, L.; Foster, B.; et al. Preclinical antitumor activity of CI-994. Invest. New Drugs 14:349-356; 1996.
17. El-Beltagi, H. M.; Martens, A. C.; Lelieveld, P.; Haroun, E. A.; Hagenbeek, A. Acetyldinaline: A new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 53:3008-3014; 1993.
18. Sgouros, G.; Yang, V.-H.; Richon, V. M.; Kelly, W. K.; Rifkind, R. A.; Marks, P. A.; Scher, H. I. Synergistic interaction of suberoylanilide hydroxamic acid (SAHA) and radiation in human prostate tumor spheroids. Proc. ASCO 27a; 2002.
19. Wozniak, A.; O'Shaughnessy, J.; Fiorica, J. Phase II trial of CI-994 in patients (pts) in advanced nonsmall cell lung cancer (NSCLC). Proc. ASCO 18:487a; 1999.
20. Nemunaitis, J. J.; Orr, D.; Eager, R.; Cunningham, C. C.; Williams, A.; Mennel, R.; Grove, W.; Olson, S. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 9(1):58-66; 2003.
21. Von Pawel, J.; Shepherd, F.; Gatzmeier, U.; Natale, R. B.; O'Brien, M. E. R.; Otterson, G. A.; Schwartzberg, L.; Kimmel, K. A.; Guyas, S.; Copley-Merriman, C.; Grove, W.; MacDonald, K. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) vs placebo (PBO) plus Gem in second-line non-small cll lung cancer (NSCLC). Proc. ASCO 21:310a; 2002.
22. Richards, D. A.; Waterhouse, D. M.; Wagener, D. J. T.; Krishnamurthi, S. S.; Rosemurgy, A.; Dasse, K. D.; Macdonald, K.; Gulyas, S.; Plante, M.; Copley-Merriman, C.; Grove, W. Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994 + G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc. ASCO 21:162a; 2002.
23. Von Pawel, J.; Koschel, G.; Crinó, L.; Olivares, J.; Gatzemeier, U.; Pauer, L.; MacDonald, K.; Gulyas, S.; Copley-Merriman, C.; Grove, W. Randomized phase II study of the oral histone deacetylase inhibitor CI-994 plus carboplatin (C) and paclitaxel (T) vs placebo (PBO) plus C/T in the first-line treatment of advanced non small cell lung cancer (NSCLC). Proc. ASCO 22:626; 2003.